Trial Profile

A Study to Assess the Efficacy and Safety of Disease modifying treatments in Patients with Multiple Sclerosis in Real-life Set-up: The Austrian MS Treatment Registry (AMSTR)

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 26 Oct 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Dimethyl fumarate (Primary) ; Fingolimod (Primary) ; Natalizumab (Primary) ; Teriflunomide (Primary)
Indications Multiple sclerosis
Focus Therapeutic Use

01 Nov 2021 Primary endpoint (annualized relapse rates (ARR) during treatment with FTY, DMF or TERI over 2 years after initiation of therapy) has been met, according to Results published in the Journal of Neurology.
01 Nov 2021 Results published in the Journal of Neurology
12 Oct 2018 Results (N=664) assessing efficacy, frequencies and reasons for treatment interruption of fingolimod, dimethyl fumarate or teriflunomide, presented at the 34th Congress of the European Committee for Treatment and Research in Multiple Sclerosis

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com